ACE2 and COVID-19: Actually, a phase II clinical trial with a recombinant human ACE2 decoy receptor (APN01) for the treatment of COVID-19 patients by intravenous administration (ClinicalTrials.gov identifier NCT04335136) failed to meet the primary outcomes (all-cause death, invasive mechanical ventilation for up to 28 days, or hospital discharge).